Article

ScreenPro FH - Screening Project for Familial Hypercholesterolemia in Central, Southern and Eastern Europe: Basic Epidemiology

Richard ČeškaThird Department of Medicine -Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles Univer-sity and General University Hospital, Prague, Czech RepublicTomáš FreibergerFaculty of Medicine, Masaryk University, Brno, Czech RepublicAndrey V. SusekovDepartment of clinical Pharmacology and therapeutics, Academy for Postgraduate Education, Ministry of Health, Russian FederationGyörgy ParaghInstitute of Internal Medicine, University of Debrecen Faculty of Medicine, Debrecen, HungaryŽeljko ReinerDepartment of Internal Medicine, Division of Metabolic Diseases, School of Medicine University of Zagreb, University Hospital Center Zagreb, Zagreb, CroatiaLâle TokgözoğluDepartment of Cardiology, Hacettepe University Faculty of Medicine, Ankara, TurkeyKatarı́na RašlováCoordination Center for Familial Hyperlipidemias, Slovak Medical University, Bratislava, SlovakiaMaciej BanachDepartment of Hypertension, Medical University of Lodz, Lodz, PolandBranislav VohnoutCoordination Center for Familial Hyperlipidemias, Slovak Medical University, Bratislava, SlovakiaAndrzej RynkiewiczDepartment of Cardiology and Cardiosurgery, Faculty of Medical Sciences, University of Warmia and Mazury, Olsztyn, PolandAssen GoudevQueen Giovanna University Hospital, Sofia, BulgariaDan Gheorghe-AndreiUniversity of Medicine Carol Davila, Colentina University Hospital, Bucharest, RomaniaDan GaițăInstitute of Cardiovascular Diseases, University of Medicine & Pharmacy Victor Babes, CardioPrevent Foundation Timisoara, RomaniaBelma PojskićCantonal hospital, Zenica, Bosnia and HerzegovinaIvan PećinDepartment of Internal Medicine, Division of Metabolic Diseases, School of Medicine University of Zagreb, University Hospital Center Zagreb, Zagreb, CroatiaMeral KayıkçıoğluCardiology Department, Ege University Medical School, Lipid Clinic, Izmir, TurkeyOlena MitchenkoМ. В. ЕжовRussian Cardiology Research and Production Center, Moscow, Russian FederationGustavs LatkovskisLatvian Institute of Cardiology and Regenerative Medicine, Faculty of Medicine, University of Latvia; Paul Stradins Clinical Uni-versity Hospital, Riga, LatviaŽaneta PetrulionienėCentre of Cardiology and Angiology, Vilnius University Hospital Santariskiu Klinikos, of Cardiology and Angiology, Vilnius, LithuaniaZlatko FrasDivision of Internal Medicine, Preventive Cardiology Unit and Medical Faculty, University of Ljubljana, University Medical Centre Ljubljana, SloveniaNebojša TasićCardiovascular research Centre, Cardiovascular Institute "Dedinje", Belgrade, SerbiaErkin М МirrakhimovNational Centre of Cardiology and Therapy named after academician Mirsaid Mirrakhimov, Kyrgyz State Medical Academy naved after I. K. Akhunbaev, Bishkek, KyrgyzstanT. M. MuratalievNational Centre of Cardiology and Therapy named after academician Mirsaid Mirrakhimov, Kyrgyz State Medical Academy naved after I. K. Akhunbaev, Bishkek, KyrgyzstanAlexander B. ShekRepublican Specialized Center of Cardiology, Tashkent, UzbekistanVladimír TukaThird Department of Medicine -Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles Univer-sity and General University Hospital, Prague, Czech RepublicAlexandros D. TselepisDepartment of Chemistry, University of Ioannina, Atherothrombosis Research Centre, Ioannina, GreeceElie MoubarakKhalid Al‐RasadiCollege of Medicine and Health Science at Sultan Qaboos University, Sultan Qaboos University Hospital, Muscat, Oman

Vnitřní lékařstvíjournal2017cs

ABI

Abstract

INTRODUCTION: Despite great recent progress, familial hypercholesterolemia (FH) is still underestimated, under-diagnosed and thus undertreated worldwide. We have very little information on exact prevalence of patients with FH in the Central, Eastern and Southern Europe (CESE) region. The aim of the study was to describe the epidemiological situation in the CESE region from data available. METHODS: All local leaders of the ScreenPro FH project were asked to provide local data on (a) expert guess of FH prevalence (b) the medical facilities focused on FH already in place (c) the diagnostic criteria used (d) the number of patients already evidenced in local database and (e) the availability of therapeutic options (especially plasma apheresis). RESULTS: With the guess prevalence of FH around 1 : 500, we estimate the overall population of 588 363 FH heterozygotes in the CESE region. Only 14 108 persons (2.4 %) were depicted in local databases; but the depiction rate varied between 0.1 % and 31.6 %. Only four out of 17 participating countries reported the the LDL apheresis availability. CONCLUSION: Our data point to the large population of heterozygous FH patients in the CESE region but low diagnostic rate. However structures through the ScreenPro FH project are being created and we can hope that the results will appear soon.Key words: diagnosis - epidemiology - familial hypercholesterolemia - screening.

Topics

Lipoproteins and Cardiovascular Health Diabetes, Cardiovascular Risks, and Lipoproteins Cholesterol and Lipid Metabolism

Identifiers

DOI: 10.36290/vnl.2017.005

Citations and references

Cited by 022 references

Metrics — AkademScholar · Coming soon